ACADIA Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

• ACADIA Pharmaceuticals Inc ACAD.OQ reported quarterly adjusted earnings of 86 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of 28 cents. The mean expectation of twenty analysts for the quarter was for earnings of 22 cents per share. Wall Street expected results to range from -10 cents to 72 cents per share.

• Revenue rose 12.4% to $259.60 million from a year ago; analysts expected $277.65 million.

• ACADIA Pharmaceuticals Inc shares had risen by 3.6% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 6.5% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 6 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for ACADIA Pharmaceuticals Inc is $25.00

This summary was machine generated from LSEG data February 26 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)